IDBS Polar
Meet IDBS Polar, the world’s first BioPharma Lifecycle Management (BPLM) platform, eliminating repetitive manual tasks, allowing you to efficiently execute your processes while curating the data you need to accelerate time to market by tackling the biggest challenges in process design, optimization, scale-up and technology transfer.
Find Out More about BPLM
ICH M10-compliant consistency, quality, and reproducibility for preclinical pharma.
Optimize workflows and integrate process and analytical data to deliver greater insight.
Introducing Polar Insight
Interactive data analytics applications, such as bioreactor comparison designed specifically for biopharma development scientists.
Find Out MoreIDBS Polar, a platform that securely manages drug progression in contexts of workflow, integration, and insight.
Polar delivers:
Workflows designed to simplify the BioPharma Lifecycle with process-aware planning, design and execution of end-to-end bioprocess and analytical unit operations.
Integrations that bring meaning to your data. Rapid integration into your development ecosystem, enabling automation and curating a process-centric data backbone.
Insight driven by highly contextualized process quality data. Enhance process understanding with out-of-the-box analytics. Transform your biopharma lifecycle with modeling & simulation.
Industry-Leading Security and Compliance: 21 CFR 11 / GxP compliant - ISO27001 certified- SOC 2 and SOC 3 reports available.
Disjointed Lifecycle – current state
60%
are using paper or Excel at some point to manage process data
30%
rework as consequence of manual processes
BioPharma Lifecycle Management platform – Future state
Read Whitepaper: Fast and effective digital transformation
Fast deployment – Short time-to-value
Transformational Journey
What makes Polar different?
Polar’s “right first time” deployment methodology uses out-of-the-box workflows paired with IDBS’ deep domain understanding and field experience. We accelerate time-to-value and reduce the risk in implementation. Let’s continue this conversation. Contact us now.
